このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Personalized and Scalable Cognitive Remediation Approaches

2026年6月19日 更新者:Alice Medalia、New York State Psychiatric Institute
The purpose of this study is to develop and pilot test personalized and scalable approaches to Cognitive Remediation (CR) for schizophrenia and schizoaffective disorder. The intent is to more clearly define the therapeutic targets important to the facilitation of cognitive and functional improvement so that clinicians know how to customize cognitive interventions and deliver treatment in a more effective, efficient and personally relevant manner.

調査の概要

詳細な説明

There are three phases of this study.

Phase 1: Development and Adaptation. The goal of this phase is to adapt currently used computer based CR approaches to make them more personalized and scalable. We will create two CR interventions which differ in choice and pacing of the cognitive exercises. This phase is complete.

Phase 2: Open Trial and Intervention Refinement. The goal of this phase is to obtain quantitative and qualitative feedback on the acceptability and usability of the interventions from participants to inform further refinement of the assessment and treatment packages. We will recruit ten subjects from an outpatient psychiatric rehabilitation program in New York City. After determining study eligibility, individuals will complete a standardized neuropsychological battery for schizophrenia assessment, and a 5-minute Tone Matching Test to assess basic auditory processing. Participants will be randomly assigned to receive one of two intervention packages, developed in Phase 1. Each session includes 60 minutes of computer-based learning activities and a 15 minute therapist-led discussion that links the computer activities to cognition as applied to daily tasks and recovery goals. Participants will complete a total of 10 sessions attending 2-3 times weekly for 5 weeks. During each session, participants will be asked to keep a log of software used. At the conclusion of this abbreviated trial, the participants will participate in focus groups in which they will be asked to provide verbal feedback on how enjoyable, engaging, and useful they perceived the computer and discussion based exercises to be. Participants will be asked to provide verbal feedback on the assessment procedures. CR clinicians will join the research team to discuss participants' engagement and their experience with administering the Tone Matching Test and interventions. Qualitative data summarized from participant logs and focus groups will be considered by the research team to refine the assessment battery, treatment parameters, and rubric of learning exercises. This phase is complete.

Phase 3: Pilot Feasibility Trial. People with a diagnosis of schizophrenia or schizoaffective disorder may be referred by their treating clinician or may respond to posted advertisements to inquire about study participation. After being informed of study procedures, interested individuals will be asked to sign a consent form that documents willingness to participate in this study. Following informed consent, participants will be asked questions about demographic characteristics (e.g. age, education, employment), medication and psychosocial treatment status, psychiatric symptoms and symptoms severity, and will complete a brief assessment of estimated Intelligence. Those with an Intelligence Quotient (IQ) estimate below 70 or meeting substance dependence criteria at the time of evaluation will be exited from the study. In the same or second assessment session, participants will complete assessments of neuropsychological ability, current functioning, and motivation for treatment. Participants will then be randomly assigned to one of two treatment conditions named "Brain Basics" or "Brain Exercises".

Each treatment condition is structured in a group format of up to 5 participants. Both treatments use commercially available computer-based training software to exercise cognitive skills such as speed of processing, attention, working memory, and verbal memory. Both conditions will entail 50 minutes on the computer and 10 minutes group discussion. In the discussion, participants review the cognitive activities they are working on and how they will help them achieve their recovery goals. The treatment phase will consist of 30 separate sessions each 60 minutes in duration, administered 3 times a week over the course of a 10-week period. Participants will be re-tested on outcome measures approximately 1 week following end of treatment, and again 3 months later.

研究の種類

介入

入学 (実際)

115

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • New York
      • Brooklyn、New York、アメリカ、11206
        • Williamsburg Clinic
      • Brooklyn、New York、アメリカ、11207
        • Institute for Community Living
      • New York、New York、アメリカ、10032
        • Nyspi/ Cumc
      • New York、New York、アメリカ、10040
        • The Bridge Inc
      • The Bronx、New York、アメリカ、10467
        • FEGS Bronx Mental Health Clinic

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  1. Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder
  2. Age 18 to 65
  3. English speaking
  4. Psychiatrically stable, verified by current living/treatment status

Exclusion Criteria:

  1. Indication of mental retardation, determined by estimated IQ of less than 70
  2. Hearing or visual impairment that precludes completing assessments
  3. Neurologic illness that may affect brain physiology (e.g. Parkinson's, seizure disorder, epilepsy)
  4. Current substance dependence symptoms in the past 6 weeks
  5. Participation in cognitive remediation in the 12 months prior to study entry.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Brain Basics for Impaired Tone Matchers
Cognitive remediation includes sensory processing training
Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
アクティブコンパレータ:Brain Basics for Intact Tone Matchers
Cognitive remediation includes sensory processing training
Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
アクティブコンパレータ:Brain Training for Impaired Tone Matcher
Cognitive remediation does not include sensory processing training
Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
アクティブコンパレータ:Brain Training for Intact Tone Matchers
Cognitive remediation does not include sensory processing training
Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Feasibility of Enrollment, Randomization and Retention
時間枠:Two years
Feasibility is measured by enrollment, acceptability of randomization defined as number initiated allocated treatment, retention of subjects defined as number completed allocated treatment
Two years

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Neurocognition From Baseline to Treatment End-point
時間枠:10 weeks
Change in neurocognition is calculated as the difference in the MATRICS Consensus Cognitive Battery Neurocognitive Composite Score between baseline and treatment end-point (10 weeks). The MATRICS Consensus Cognitive Battery Neurocognitive Composite T-Score is a scaled score calculated from the following component subscales: a) working memory; b) attention/vigilance; c) verbal learning; d) visual learning; e) processing speed; f) reasoning and problem solving. The mean T-score is 50 with a standard deviation of 10. Higher scores on the scale mean better outcomes. Higher change scores mean better outcomes.
10 weeks
Change in Neurocognition From Baseline to 3-month Follow-up
時間枠:5.5 to 6 months
Change in neurocognition is calculated as the difference in the MATRICS Consensus Cognitive Battery Neurocognitive Composite Score between baseline and 3-month follow-up (5.5 to 6 months). The MATRICS Consensus Cognitive Battery Neurocognitive Composite T-Score is a scaled score calculated from the following component subscales: a) working memory; b) attention/vigilance; c) verbal learning; d) visual learning; e) processing speed; f) reasoning and problem solving. The mean T-score is 50 with a standard deviation of 10. Higher scores on the scale mean better outcomes. Higher change scores mean better outcomes.
5.5 to 6 months

その他の成果指標

結果測定
メジャーの説明
時間枠
Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR)
時間枠:10 weeks
Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR), a 21 item 7-point Likert type scale designed to assess a participant's subjective experience of an activity, specifically in an experimental setting (e.g. "I enjoyed doing this activity very much"). The IMI-SR will be administered at the first and last treatment sessions.
10 weeks
Perceived Competency Scale (PCS)
時間枠:10 weeks
The PCS consists of 4 items on a 7-point Likert-type scale that assess feelings of competency when performing computer-based learning activities, with higher scores indicating greater perceived competency. The PCS will be administered at the first and last treatment sessions.
10 weeks
Change in Tone Matching Ability From Baseline to Treatment End-point
時間枠:10 weeks
Change in Tone Matching (percent correct) will be calculated as the difference between scores measured at baseline and treatment end-point (10 weeks), using pairs of 100-ms tones in series, with 500-ms inter-tone interval. The values on this scale range from 0% to 100% where higher scores mean better outcomes. Higher change scores mean better outcomes.
10 weeks
Change in UCSD Performance-Based Skills Assessment (UPSA)-Brief From Baseline to Treatment End-point
時間枠:10 weeks
The UPSA - Brief is a proxy measure of daily functioning skills. Change from baseline to treatment end-point (10 weeks) will be assessed as the difference between the two scores. The scale score can range from 0 to 100. Higher scores mean better outcomes. Higher change scores mean better outcomes.
10 weeks
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) - Treatment End-point
時間枠:10 weeks
The SCI-PANSS is a semi-structured interview containing 30 items that assess symptoms of psychotic disorders including positive, negative and general psychopathology. Change from baseline to treatment end-point (10 weeks) will be assessed. Higher scores mean higher symptom severity. Change is calculated as the difference between the two scores. Greater change scores mean greater symptom improvement.
10 weeks
Change in Tone Matching Ability From Baseline to 3-month Follow up
時間枠:5.5 to 6 months
Change in Tone Matching (percent correct) will be calculated as the difference in scores assessed at baseline and 3-month follow-up (5.5 to 6 months), using pairs of 100-ms tones in series, with 500-ms inter-tone interval. The values on this scale range from 0% to 100% where higher scores mean better outcomes. Greater change scores mean greater improvement.
5.5 to 6 months
Change in UCSD Performance-Based Skills Assessment (UPSA)-Brief From Baseline to 3-month Follow-up
時間枠:5.5 to 6 months
The UPSA-Brief is a proxy measure for daily functioning skills. The scale score ranges from 0-100. Change from baseline to 3-month follow-up (5.5-6 months) will be assessed as the difference between the two scores. Higher scores mean better outcomes. Higher change scores mean better outcomes.
5.5 to 6 months
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) - 3-month Follow-up
時間枠:5.5 to 6 months
The SCI-PANSS is a semi-structured interview containing 30 items that assess symptoms of psychotic disorders including positive, negative and general psychopathology. Change from baseline to 3-month follow-up will be assessed.
5.5 to 6 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Alice Medalia, PhD、NYSPI

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2013年9月1日

一次修了 (実際)

2017年10月2日

研究の完了 (実際)

2019年3月20日

試験登録日

最初に提出

2013年9月13日

QC基準を満たした最初の提出物

2013年9月13日

最初の投稿 (推定)

2013年9月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月17日

QC基準を満たした最後の更新が送信されました

2026年6月19日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

This trial started enrolling participants before January 1, 2019.

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する